|PRM -- UK Stock|| |
GBp 3.62 0.13 3.47%
Dr. Malcolm Ward is Chief Technical Officer London Research Facility of Proteome Sciences PLC. Malcolm Ward joined Proteome Sciences plc in May 2001 having previously worked for GlaxoWellcome for 12 years, in protein mass spectrometry. He was involved in the establishment of the new leading edge protein separation and mass spectrometry facility at the Institute of Psychiatry, Kings College London. His research team is involved in biomarker discovery, validation and assay development. His academic qualifications include a MS in Molecular Biology from the University of Hertfordshire in 1996 and a Graduateship from the Royal Society of Chemistry in 1992. He obtained a PhD in Applied Proteomics at Kings College, London in 2009..
Executive Since 2011
44 20 7043 2116 http://www.proteomics.com
The company has return on total asset (ROA)
of (13.16) %
which means that it has lost $13.16 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (16.4) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 9.11 M in total debt. Proteome Sciences plc has Current Ratio of 0.3 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers. The company was incorporated in 1993 and is headquartered in London, the United Kingdom. Proteome Sciences operates under Diagnostics Research classification in UK and traded on London Stock Exchange. It employs 34 people.Proteome Sciences plc (PRM) is traded on London Stock Exchange in UK. It is located in Hamilton House and employs 34 people.
Proteome Sciences plc Leadership Team
|William Dawson, Non-Executive Director|
|Roger McDowell, Non-Executive Director|
|Christopher Pearce, Chief Executive, Executive Director|
|Ian Pike, COO and Executive Director|
|Richard Dennis, Chief Commercial Officer|
|Malcolm Ward, Chief Technical Officer of London Research Facility|
|Martin Diggle, Non-Executive Director|
|Jeremy Haigh, CEO, Director|
|Josef Schwarz, Head of Projects and Production - Proteome Sciences RandD|
|Ursula Ney, Non-Executive Director|
|Glenn Barney, VP of Bus. Devel. - USA|
|Gee Chee, Director of Personalised Medicine|
|Geoffrey Ellis, Fin. Director, Company Secretary and Executive Director|
Stock Performance Indicators